Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 17/20 | 0.55 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.49 |
| ▸ | SGK1 | O00141 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970942 | 0.94 | MAP2K4 (0.56) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3971235 | 0.92 | SGK1 (0.56) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3964181 | 0.91 | SGK1 (0.57) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3968444 | 0.90 | MAP2K4 (0.49) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3968048 | 0.88 | MAP2K4 (0.53) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3968443 | 0.87 | SGK1 (0.58) | MAP2K4SGK1 | |
| SCHEMBL3967980 | 0.87 | MAP2K4 (0.62) | MAP2K4MAP2K7 | |
| SCHEMBL3962444 | 0.86 | SGK1 (0.61) | MAP2K4SGK1 | |
| SCHEMBL3972626 | 0.86 | MAP2K4 (0.52) | MAP2K4MAP2K7SGK1 | |
| SCHEMBL3971863 | 0.85 | MAP2K4 (0.66) | MAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | MAP2K4 101/4885MAP2K7 51/4885SGK1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.